About Covance

Covance Inc., a global contract research organization (CRO), is the world’s most comprehensive drug development company. 

Covance Inc., the drug development business of LabCorp®, is the world’s most comprehensive drug development company, dedicated to advancing healthcare and delivering Solutions Made Real®

Our unique perspectives, built from decades of scientific expertise and precision delivery of the largest volume of drug development data in the world, along with our innovative technology solutions, help our clients identify new approaches and anticipate tomorrow’s challenges as they evolve. Together with our clients, Covance transforms today’s healthcare challenges into tomorrow’s solutions. 

We also offer laboratory testing services to the chemical/agrochemical industries and are a market leader in toxicology services, central laboratory services, discovery services and a top global provider of Phase III clinical trial management services.

Laboratory Corporation of America® Holdings (NYSE: LH), an S&P 500 company, is a world leading life sciences company, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostic solutions, brings innovative medicines to patients faster and develops technology-enabled solutions to change the way care is provided. With net revenue in excess of $8.5 billion in 2015, LabCorp’s 50,000 employees serve clients in 60 countries. 

Photo of a Covance scientist holding a slide working in a lab.
Mission, Vision and Values

Our mission is to improve health and improve lives.

Our vision is to be recognized by clients as:

  • The undisputed leader in providing drug development services
  • trusted partner whose hallmarks are
    • Great people
    • High-quality data
    • A proven track record of integrating and streamlining the development process

Our values are to strive for operational and service excellence through a relentless focus on People, Process and Clients.

Our History
2015 LabCorp® (NYSE: LH) acquires Covance Inc., creating the world’s leading healthcare diagnostics company, providing comprehensive clinical laboratory services and end-to-end solutions for drug and diagnostics development and commercialization.
2011 Takeda Pharmaceuticals International, Inc. chooses Covance as one of its strategic partners to plan and execute global development programs to support new compounds in all therapeutic areas, except oncology.
2010 Covance signs landmark agreement with Sanofi-Aventis for a 10-year strategic R&D alliance and acquires their Porcheville, France and Alnwick, United Kingdom sites.

Covance acquires Merck's Seattle-based Gene Expression Laboratory. Under the agreement, Merck has committed to a five-year $145 million contract to purchase genomic analysis services from Covance.

Covance acquires Swiss Pharma Contract, a clinical research company based in Basel, Switzerland.


Covance purchases minority equity stake in Caprion Proteomics, the leading provider of proteomics-based services to the pharmaceutical industry, to further enhance its biomarkers service offering to clients.

Covance makes CRO history with the most comprehensive drug development partnership in the industry. Covance acquires Lilly’s Greenfield, Indiana campus and executes a 10-year service agreement with Lilly.


In celebration of their 10-year anniversary, Covance announces our partnership with CARE to support the Covance-CARE Early Childhood Development (ECD) Initiative for Orphans and Vulnerable Children in Rwanda.

Covance opens Central Labs facility in Shanghai, China.

2006 Covance announces acquisition of eight early phase clinical pharmacology sites of Radiant Research, Inc. Opens the largest toxicology expansion in Madison, Wisconsin.
2002 Covance acquires Virtual Central Labs, now known as Local Laboratory Services.

Central STET laboratory opens in Singapore to serve fast-growing East Asian market.

Covance expands pharmaceutical analysis facility in Harrogate, U.K. and Phase I clinical research unit in Leeds, U.K.

1998 Covance acquires the Berkeley (California) Antibody Company.
1997 Covance begins operations as an independent, publicly traded company on the New York Stock Exchange (NYSE) after our official spin-off from Corning Incorporated.
In the News

Visit our Press & News section to read the latest press releases.

Update your Covance communications preferences